A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Carcinoma of the colon and/or rectum
Disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
ECOG performance status 0-1
Adequate hematological, renal and liver function
You may not be if
Prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (EGFR)
Prior treatment with irinotecan
Radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
CNS metastasis
History of or active autoimmune disorders/conditions
Clareo Health | A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
